Abstract
Pregnancy-associated osteoporosis (PAO) is a rare pathology affecting women in pregnancy or the postpartum period. During normal pregnancy and lactation, there are substantial physiological changes in the woman’s skeletal structure as well as calcium homeostasis to meet demands of the developing fetus. While these adaptations and generally of no clinical consequence for the mother, and subsequently resolve postpartum, a small number of women will develop osteoporosis and suffer from non-traumatic fragility fractures. Due to the rarity of PAO, systematic study to date has been limited. Etiology is poorly understood, but endocrine effects, nutrient deficiency, genetic predisposition, biomechanical factors, and medication exposures are likely to play a role. Management of PAO is not well understood, due both to a poor evidence base and the rarity of the condition. However, traditional osteoporosis drugs such as bisphosphonates, denosumab, and teriparatide have all been reported in literature. Early diagnosis and treatment of these patients are especially important in the prevention of reoccurrence fractures and to improve the quality of life for these patients.
Similar content being viewed by others
References
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet. 2011;377(9773):1276–87.
Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–70.
Dunne F, Walters B, Marshall T, et al. Pregnancy associated osteoporosis. Clin Endocrinol. 1993;39(4):487–90.
Nordin B, Roper A. Post-pregnancy osteoporosis. A syndrome P. Lancet. 1955;268:431–434.
Choe EY, Song JE, Park KH, et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab. 2012;30(5):596–601.
Hellmeyer L, Hadji P, Ziller V. Osteoporosis in pregnancy Geburtshilfeund Frauenheilkunde. 2004;64:38–45.
O’sullivan S, Grey A, Singh R, et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006;17(7):1008–12.
Hadji P, Boekhoff J, Hahn M, et al. Pregnancy-associated osteoporosis: a case-control study. Osteoporos Int. 2017;28(4):1393–9.
Ghannam N, Hammami M, Bakheet S, et al. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation. Calcif Tissue Int. 1999;65(1):23–8.
Lebel E, Mishukov Y, Babchenko L, et al. Bone mineral density in gravida: effect of pregnancies and breast-feeding in women of differing ages and parity. J Osteoporos. 2014;2014.
Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168(4):1265–70.
Ozdemir D, Tam A, Dirikoc A, et al. Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int. 2015;26(1):415–8.
Tuna F, Akleylek C, Özdemir H, et al. Risk factors, fractures, and management of pregnancy-associated osteoporosis: a retrospective study of 14 Turkish patients. Gynecol Endocrinol. 2020;36(3):238–42.
Kovacs C, Ralston S. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporos Int. 2015;26(9):2223–41.
Sanz-Salvador L, García-Pérez MÁ, Tarin JJ, et al. Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. Eur J Endocrinol. 2014;172(2):R53-65.
Polat SB, Evranos B, Aydin C, et al. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol. 2015;31(7):522–5.
Silva L, Sampaio L, Pinto J, et al. Osteoporotic fractures in pregnancy-conjunction of factors? Acta Reumatologica Portuguesa. 2009;34(4):641–5.
Sharma J, Sharma S, Usha B, et al. Cross-sectional study of serum parathyroid hormone level in high-risk pregnancies as compared to nonpregnant control. Indian J Endocrinol Metab. 2016;20(1):92.
Hysaj O, Marqués-Gallego P, Richard A, et al. Parathyroid hormone in pregnancy: vitamin D and other determinants. Nutrients. 2021;13(2):360.
Yadav S, Yadav YS, Goel MM, et al. Calcitonin gene-and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control study. Arch Gynecol Obstet. 2014;290(5):897–903.
RiGGs BL, Arnaud CD, Reynolds JC, et al. Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. J Clin Investig. 1971;50(10):2079–83.
Sweeney LL, Malabanan AO, Rosen H. Decreased calcitriol requirement during pregnancy and lactation with a window of increased requirement immediately post partum. Endocr Pract. 2010;16(3):459–62.
Peris P, Guanabens N, Monegal A, et al. Pregnancy associated osteoporosis: the familial effect. Clin Exp Rheumatol. 2002;20(5):697–700.
Butscheidt S, Delsmann A, Rolvien T, et al. Mutational analysis uncovers monogenic bone disorders in women with pregnancy-associated osteoporosis: three novel mutations in LRP5, COL1A1, and COL1A2. Osteoporos Int. 2018;29(7):1643–51.
Kasahara K, Mimura T, Moritani S, et al. Subchondral insufficiency fracture of the femoral head in a pregnant woman with pre-existing anorexia nervosa. Tohoku J Exp Med. 2018;245(1):1–5.
Clemetson I, Popp A, Lippuner K, et al. Postpartum osteoporosis associated with proximal tibial stress fracture. Skeletal Radiol. 2004;33(2):96–8.
Gehlen M, Lazarescu AD, Hinz C, et al. Long-term outcome of patients with pregnancy and lactation-associated osteoporosis (PLO) with a particular focus on quality of life. Clin Rheumatol. 2019;38(12):3575–83.
Toba M, Terauchi M, Moriwaki M, et al. Fractures within 2 years of an obstetric hospitalization: analysis of nationwide administrative data in Japan. J Bone Miner Metab. 2022:1–7.
Hardcastle S, Yahya F, Bhalla A. Pregnancy-associated osteoporosis: a UK case series and literature review. Osteoporos Int. 2019;30(5):939–48.
Di Gregorio S, Danilowicz K, Rubin Z, et al. Osteoporosis with vertebral fractures associated with pregnancy and lactation. Nutrition. 2000;16(11–12):1052–5.
Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8(4):371–8.
Ramachandran T. Background radiation, people and the environment. Indian Journal of Environmental Protection. 2011;28(10);914–925
Vokes T, Bachman D, Baim S, et al. Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):37–46.
Bauer J, Müller D, Ambekar A, et al. Detection of osteoporotic vertebral fractures using multidetector CT. Osteoporos Int. 2006;17(4):608–15.
Kraemer B, Schneider S, Rothmund R, et al. Influence of pregnancy on bone density: a risk factor for osteoporosis? Measurements of the calcaneus by ultrasonometry. Arch Gynecol Obstet. 2012;285(4):907–12.
Smith R, Athanasou N, Ostlere S, et al. Pregnancy-associated osteoporosis. QJM: An Int J Med. 1995;88(12):865–878.
Kyvernitakis I, Reuter T, Hellmeyer L, et al. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int. 2018;29(1):135–42.
Li L-J, Zhang J, Gao P, et al. Clinical characteristics and bisphosphonates treatment of rare pregnancy-and lactation-associated osteoporosis. Clin Rheumatol. 2018;37(11):3141–3150.
Ott SM. Long-term safety of bisphosphonates. Oxford University Press; 2005. p. 1897–1899.
Ringe J, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int. 2005;16(12):2063–8.
Robinson DE, Ali MS, Pallares N, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. 2021;36(5):820–32.
Jain S, Camacho P. Adverse effects of antiresorptive therapy. Osteoporosis: Springer; 2021. p. 135–48.
Rosini S, Rosini S, Bertoldi I, et al. Understanding bisphosphonates and osteonecrosis of the jaw: uses and risks. Eur Rev Med Pharmacol Sci. 2015;19(17):3309–17.
Patlas N, Golomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68–73.
Ioannis SP, Chrysoula LG, Aikaterini K, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones. 2011;10(4):280–91.
Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146–8.
Hong N, Kim JE, Lee SJ, et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy-and lactation-associated osteoporosis. Clin Endocrinol. 2018;88(5):652–8.
Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP, et al. Case report: teriparatide treatment in a case of severe pregnancy-and lactation-associated osteoporosis. Hormones. 2012;11(4):495–500.
Winarno A, Kyvernitakis I, Hadji P. Successful treatment of 1–34 parathyroid hormone (PTH) after failure of bisphosphonate therapy in a complex case of pregnancy associated osteoporosis and multiple fractures. Z Geburtshilfe Neonatol. 2014;218(04):171–3.
Lee SH, Hong M-K, Park SW, et al. A case of teriparatide on pregnancy-induced osteoporosis. Journal of Bone Metabolism. 2013;20(2):111–4.
Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin. 2008;24(2):377–84.
Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312–21.
Vahle JL, Anderson U, Blomme EA, et al. Use of toxicogenomics in drug safety evaluation: current status and an industry perspective. Regul Toxicol Pharmacol. 2018;96:18–29.
Gilsenan A, Harding A, Kellier-Steele N, et al. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018;29(10):2335–43.
Ozturk C, Atamaz FC, Akkurt H, et al. Pregnancy-associated osteoporosis presenting severe vertebral fractures. J Obstetrics Gynaecol Res. 2014;40(1):288–92.
Tanriover MD, Oz SG, Sozen T, et al. Pregnancy-and lactation-associated osteoporosis with severe vertebral deformities: can strontium ranelate be a new alternative for the treatment? Spine J. 2009;9(4):e20–4.
Nakamura Y, Kamimura M, Ikegami S, et al. A case series of pregnancy-and lactation-associated osteoporosis and a review of the literature. Ther Clin Risk Manag. 2015;11:1361.
Sánchez A, Zanchetta MB, Danilowicz K. Two cases of pregnancy-and lactation-associated osteoporosis successfully treated with denosumab. Clin Cases Miner Bone Metab. 2016;13(3):244.
Ijuin A, Yoshikata H, Asano R, et al. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: a case study. Taiwan J Obstet Gynecol. 2017;56(6):863–6.
Bayram S, Ozturk C, Sivrioglu K, et al. Kyphoplasty for pregnancy-associated osteoporotic vertebral fractures. Joint Bone Spine. 2006;73(5):564–6.
Terzi R, Terzi H, Özer T, et al. A rare cause of postpartum low back pain: pregnancy-and lactation-associated osteoporosis. BioMed Res Int. 2014;2014.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Presentations : None to date.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kovalev, V., Fang, W.H., Pak, T. et al. Pregnancy-Associated Osteoporosis: A Literature Review. Clinic Rev Bone Miner Metab 21, 14–20 (2023). https://doi.org/10.1007/s12018-023-09287-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12018-023-09287-8